Surprised you still don't get it: Amgen is used because they can't use Azer-Cel at this stage. Waiting for Azer-Cel to be approved and starting then would take them to the end of the 2030s.
Always risky to follow The Queens song" I wan' it all and I wan' it now! "
Read my post again, they most likely will get Azer-Cel approved but will anyone want to have it then?
Look at CHM's CDH17, the world's first direct solid cancer CAR-T. In high demand 4 years ago, unwanted now. That's the CAR-T reality.
More examples, the fall of ALA as reality about their iNKT-CAR-T sinks in. They still haven't got their IND as the FDA concentrates on other technologies and keeps them waiting and sending them home to submit another application over and over again.
More CAR-Ts unwanted such as CHMs NK-cell CAR-Ts, GBM-CAR-T.........
Developments of other techs have taken over, such as the move from radiotherapy imaging to treating. That's more efficient and costs just about 1/5 or less than today's CAR-T treatments.
GLTA
IMU Price at posting:
2.4¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)